162 related articles for article (PubMed ID: 37540673)
1. Two opposing gene expression patterns within ATRX aberrant neuroblastoma.
van Gerven MR; Schild L; van Arkel J; Koopmans B; Broeils LA; Meijs LAM; van Oosterhout R; van Noesel MM; Koster J; van Hooff SR; Molenaar JJ; van den Boogaard ML
PLoS One; 2023; 18(8):e0289084. PubMed ID: 37540673
[TBL] [Abstract][Full Text] [Related]
2. Mutational spectrum of ATRX aberrations in neuroblastoma and associated patient and tumor characteristics.
van Gerven MR; Bozsaky E; Matser YAH; Vosseberg J; Taschner-Mandl S; Koster J; Tytgat GAM; Molenaar JJ; van den Boogaard M
Cancer Sci; 2022 Jun; 113(6):2167-2178. PubMed ID: 35384159
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma.
George SL; Lorenzi F; King D; Hartlieb S; Campbell J; Pemberton H; Toprak UH; Barker K; Tall J; da Costa BM; van den Boogaard ML; Dolman MEM; Molenaar JJ; Bryant HE; Westermann F; Lord CJ; Chesler L
EBioMedicine; 2020 Sep; 59():102971. PubMed ID: 32846370
[TBL] [Abstract][Full Text] [Related]
4. ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures.
Qadeer ZA; Valle-Garcia D; Hasson D; Sun Z; Cook A; Nguyen C; Soriano A; Ma A; Griffiths LM; Zeineldin M; Filipescu D; Jubierre L; Chowdhury A; Deevy O; Chen X; Finkelstein DB; Bahrami A; Stewart E; Federico S; Gallego S; Dekio F; Fowkes M; Meni D; Maris JM; Weiss WA; Roberts SS; Cheung NV; Jin J; Segura MF; Dyer MA; Bernstein E
Cancer Cell; 2019 Nov; 36(5):512-527.e9. PubMed ID: 31631027
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemistry for ATRX Can Miss ATRX Mutations: Lessons From Neuroblastoma.
Chami R; Marrano P; Teerapakpinyo C; Arnoldo A; Shago M; Shuangshoti S; Thorner PS
Am J Surg Pathol; 2019 Sep; 43(9):1203-1211. PubMed ID: 31290759
[TBL] [Abstract][Full Text] [Related]
6. Association of age at diagnosis and genetic mutations in patients with neuroblastoma.
Cheung NK; Zhang J; Lu C; Parker M; Bahrami A; Tickoo SK; Heguy A; Pappo AS; Federico S; Dalton J; Cheung IY; Ding L; Fulton R; Wang J; Chen X; Becksfort J; Wu J; Billups CA; Ellison D; Mardis ER; Wilson RK; Downing JR; Dyer MA;
JAMA; 2012 Mar; 307(10):1062-71. PubMed ID: 22416102
[TBL] [Abstract][Full Text] [Related]
7. Clinical features of ATRX or DAXX mutated neuroblastoma.
Kurihara S; Hiyama E; Onitake Y; Yamaoka E; Hiyama K
J Pediatr Surg; 2014 Dec; 49(12):1835-8. PubMed ID: 25487495
[TBL] [Abstract][Full Text] [Related]
8. Functional Loss of
Graham MK; Kim J; Da J; Brosnan-Cashman JA; Rizzo A; Baena Del Valle JA; Chia L; Rubenstein M; Davis C; Zheng Q; Cope L; Considine M; Haffner MC; De Marzo AM; Meeker AK; Heaphy CM
Mol Cancer Res; 2019 Dec; 17(12):2480-2491. PubMed ID: 31611308
[TBL] [Abstract][Full Text] [Related]
9. Study of chromatin remodeling genes implicates SMARCA4 as a putative player in oncogenesis in neuroblastoma.
Bellini A; Bessoltane-Bentahar N; Bhalshankar J; Clement N; Raynal V; Baulande S; Bernard V; Danzon A; Chicard M; Colmet-Daage L; Pierron G; Le Roux L; Planchon JM; Combaret V; Lapouble E; Corradini N; Thebaud E; Gambart M; Valteau-Couanet D; Michon J; Louis-Brennetot C; Janoueix-Lerosey I; Defachelles AS; Bourdeaut F; Delattre O; Schleiermacher G
Int J Cancer; 2019 Nov; 145(10):2781-2791. PubMed ID: 31018240
[TBL] [Abstract][Full Text] [Related]
10. The chromatin remodeller ATRX facilitates diverse nuclear processes, in a stochastic manner, in both heterochromatin and euchromatin.
Truch J; Downes DJ; Scott C; Gür ER; Telenius JM; Repapi E; Schwessinger R; Gosden M; Brown JM; Taylor S; Cheong PL; Hughes JR; Higgs DR; Gibbons RJ
Nat Commun; 2022 Jun; 13(1):3485. PubMed ID: 35710802
[TBL] [Abstract][Full Text] [Related]
11. TERT-mediated and ATRX-mediated Telomere Maintenance and Neuroblastoma.
Duan XF; Zhao Q
J Pediatr Hematol Oncol; 2018 Jan; 40(1):1-6. PubMed ID: 28452859
[TBL] [Abstract][Full Text] [Related]
12. Loss of atrx cooperates with p53-deficiency to promote the development of sarcomas and other malignancies.
Oppel F; Tao T; Shi H; Ross KN; Zimmerman MW; He S; Tong G; Aster JC; Look AT
PLoS Genet; 2019 Apr; 15(4):e1008039. PubMed ID: 30970016
[TBL] [Abstract][Full Text] [Related]
13. Aberrant calcium/calmodulin-dependent protein kinase II (CaMKII) activity is associated with abnormal dendritic spine morphology in the ATRX mutant mouse brain.
Shioda N; Beppu H; Fukuda T; Li E; Kitajima I; Fukunaga K
J Neurosci; 2011 Jan; 31(1):346-58. PubMed ID: 21209221
[TBL] [Abstract][Full Text] [Related]
14. Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations.
Casar-Borota O; Boldt HB; Engström BE; Andersen MS; Baussart B; Bengtsson D; Berinder K; Ekman B; Feldt-Rasmussen U; Höybye C; Jørgensen JOL; Kolnes AJ; Korbonits M; Rasmussen ÅK; Lindsay JR; Loughrey PB; Maiter D; Manojlovic-Gacic E; Pahnke J; Poliani PL; Popovic V; Ragnarsson O; Schalin-Jäntti C; Scheie D; Tóth M; Villa C; Wirenfeldt M; Kunicki J; Burman P
J Clin Endocrinol Metab; 2021 Mar; 106(4):1183-1194. PubMed ID: 33106857
[TBL] [Abstract][Full Text] [Related]
15. Telomerase activation by genomic rearrangements in high-risk neuroblastoma.
Peifer M; Hertwig F; Roels F; Dreidax D; Gartlgruber M; Menon R; Krämer A; Roncaioli JL; Sand F; Heuckmann JM; Ikram F; Schmidt R; Ackermann S; Engesser A; Kahlert Y; Vogel W; Altmüller J; Nürnberg P; Thierry-Mieg J; Thierry-Mieg D; Mariappan A; Heynck S; Mariotti E; Henrich KO; Gloeckner C; Bosco G; Leuschner I; Schweiger MR; Savelyeva L; Watkins SC; Shao C; Bell E; Höfer T; Achter V; Lang U; Theissen J; Volland R; Saadati M; Eggert A; de Wilde B; Berthold F; Peng Z; Zhao C; Shi L; Ortmann M; Büttner R; Perner S; Hero B; Schramm A; Schulte JH; Herrmann C; O'Sullivan RJ; Westermann F; Thomas RK; Fischer M
Nature; 2015 Oct; 526(7575):700-4. PubMed ID: 26466568
[TBL] [Abstract][Full Text] [Related]
16. The chromatin remodeling protein ATRX positively regulates IRF3-dependent type I interferon production and interferon-induced gene expression.
Stilp AC; Scherer M; König P; Fürstberger A; Kestler HA; Stamminger T
PLoS Pathog; 2022 Aug; 18(8):e1010748. PubMed ID: 35939517
[TBL] [Abstract][Full Text] [Related]
17. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T
Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
[No Abstract] [Full Text] [Related]
18. Loss of p53 suppresses replication stress-induced DNA damage in ATRX-deficient neuroblastoma.
Akter J; Katai Y; Sultana P; Takenobu H; Haruta M; Sugino RP; Mukae K; Satoh S; Wada T; Ohira M; Ando K; Kamijo T
Oncogenesis; 2021 Nov; 10(11):73. PubMed ID: 34743173
[TBL] [Abstract][Full Text] [Related]
19. Neuroblastoma after childhood: prognostic relevance of segmental chromosome aberrations, ATRX protein status, and immune cell infiltration.
Berbegall AP; Villamón E; Tadeo I; Martinsson T; Cañete A; Castel V; Navarro S; Noguera R
Neoplasia; 2014 Jun; 16(6):471-80. PubMed ID: 25077701
[TBL] [Abstract][Full Text] [Related]
20. ATRX, a guardian of chromatin.
Aguilera P; López-Contreras AJ
Trends Genet; 2023 Jun; 39(6):505-519. PubMed ID: 36894374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
